A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

May 31, 2005

Conditions
Schizophrenia
Interventions
DRUG

Risperidone

Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6

DRUG

Ziprasidone

Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6

Trial Locations (5)

100083

Pfizer Investigational Site, Beijing

100088

Pfizer Investigational Site, Beijing

200030

Pfizer Investigational Site, Shanghai

210029

Pfizer Investigational Site, Nanjing

510370

Pfizer Investigational Site, Guangzhou

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00645372 - A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients | Biotech Hunter | Biotech Hunter